UPC Stock Forecast: Universe Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 25 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Universe Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (63): Sales and profits are climbing, and climbing faster than before.
Volatility (8): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
UPC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on UPC, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
UPC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
UPC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.3×
- Price / book
- 0.0×
- EV / EBITDA
- —
Cheaper than 86% of US stocks
Cheaper than 99% of US stocks
- Revenue growth (YoY)
- −1.3%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −11.8%
- Net margin
- −10.9%
Higher than 26% of US stocks
Higher than 25% of US stocks
Higher than 20% of US stocks
- Return on equity
- −3.5%
- Return on assets
- −1.7%
- Dividend yield
- —
Higher than 41% of US stocks
Higher than 38% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Universe Pharmaceuticals, Inc. has a market value of $5.9M.
Universe Pharmaceuticals, Inc. employs 216 people.
Data provided by Twelve Data
UPC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at UPC’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Universe Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about UPC
How does Ticker Nerd's model rank UPC?
As at 21 Nov 2026, Universe Pharmaceuticals, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (63 of 100).
What is the UPC stock forecast for 2030?
No analyst covering Universe Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UPC are extrapolating price history, which says nothing about the business.
What does Universe Pharmaceuticals, Inc. do?
Universe Pharmaceuticals Inc. Class A Ordinary Shares represents the equity of a China-based pharmaceutical company focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. The company also offers biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements sourced from third-party manufacturers.
About Universe Pharmaceuticals, Inc.
Universe Pharmaceuticals Inc. Class A Ordinary Shares represents the equity of a China-based pharmaceutical company focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. The company also offers biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements sourced from third-party manufacturers. Its product portfolio is designed to address common health conditions, including chronic ailments associated with aging, as well as cold and flu needs. Operating through its subsidiaries, Universe Pharmaceuticals serves customers in domestic and international markets and participates in the broader healthcare supply chain through production, distribution, and commercialization activities. Headquartered in Ji’an, Jiangxi, China, the company issues Class A ordinary shares as part of a dual-class share structure that is used in its corporate governance framework.
CEO Mr. Gang Lai · 216 employees · China · https://www.universe-pharmacy.com